A Phase 3 Study to Compare AMG 510 With Docetaxel in NSCLC SubjectsWith KRAS p.G12C Mutation (CodeBreak 200)
- Conditions
- Previously treated locally advanced and unresectable or metastatic nonsmallcell lung cancer (NSCLC) with KRAS p.G12C mutationMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2019-003582-18-DE
- Lead Sponsor
- Amgen, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 330
• Subject or subject's legally acceptable representative has provided
informed consent prior to initiation of any study specific
activities/procedures.
• Age = 18 years of age
• Have documentation of KRAS p.G12C mutation confirmed by central
testing through the current protocol or have documentation of KRAS
p.G12C mutation through Amgen Study 20190294 prior to enrollment.
• Subjects will have received and progressed or experienced disease
recurrence on or after receiving at least 1 prior systemic therapy for
locally advanced and unresectable or metastatic disease. Prior treatment
must include a platinum-based doublet chemotherapy and checkpoint
inhibitor for advanced or metastatic disease, either given as one line of
therapy or as individual lines of therapy unless the subject has a medical
contraindication to one of the required therapies. If the subject has a
medical contraindication to a required therapy, the subject may be
enrolled only after the investigator discusses and obtains approval from
the Amgen medical monitor.
a) Adjuvant therapy will count as a line of therapy if the subject
progressed on or within 6 months of adjuvant therapy administration.
b) In locally advanced and unresectable NSCLC, disease progression on
or within 6 months of end of prior curatively intended multimodal
therapy will count as a line of therapy. If chemoradiation is followed by
planned systemic therapy without documented progression between
chemoradiation and systemic therapy, the entire treatment course
counts as one line of therapy.
• Subjects must have archived tumor tissue samples (formalin fixed,
paraffin embedded [FFPE] sample [FFPE of excisional, core needle, or
fine needle aspirates] collected within 5 years) or be willing to undergo
pre-treatment tumor biopsy (excisional, core needle, or fine needle
aspirates) prior to enrollment.
• Measurable disease per RECIST v1.1 criteria. Lesions previously
radiated are not considered measurable unless they have progressed
after radiation.
• ECOG Performance Status of = 1
• Adequate hematologic laboratory assessments
• Life expectancy of > 3 months, in the opinion of the investigator
• Adequate liver function
• International normalized ratio (INR) and activated partial
thromboplastin time = 1.5 x ULN
• Serum creatinine = 1.5 x ULN OR creatinine clearance = 60 mL/min.
Cockcroft-Gault formula will be used for creatinine clearance calculation.
Twenty-four hour urine collection is not required but is allowed.
• QTc = 470 msec in females and = 450 msec in males
• Ability to take oral medications and willing to record daily adherence
to investigational product
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 250
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 80
• Subjects have received prior docetaxel in unresectable or metastatic
setting.
• Mixed small-cell lung cancer or mixed NSCLC histology
• Previously identified driver mutation (according to local standard of
care or guidelines) other than KRAS p.G12C for which an approved
therapy is available (including EGFR, ALK, etc).
• Active brain metastases. Subjects who have had brain metastases
resected or have received whole brain radiation therapy ending at least
4 weeks (or stereotactic radiosurgery ending at least 2 weeks) prior to
study day 1 are eligible if they meet all of the following criteria: a)
residual neurological symptoms grade = 2; b) on stable doses of dexamethasone or equivalent for at least 2 weeks, if applicable; and c)
follow-up MRI performed within 30 days prior to enrollment shows no
progression or new lesions appearing.
• Leptomeningeal disease.
• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring
recurrent drainage procedures at a frequency greater than monthly.
Subjects with PleurX catheters in place may be considered for the study
with Medical Monitor approval.
Other Medical Conditions
• Known history of Human Immunodeficiency Virus (HIV) infection
• Exclusion of hepatitis infection based on the following results and/or
criteria:
a) Positive hepatitis B surface antigen (HepBsAg)
b) Negative HepBsAg with a positive for hepatitis B core antibody
(Hepatitis B core antibody testing is not required for screening, however
if this is done and is positive, then hepatitis B surface antibody [Anti-
HBs] testing is necessary. Undetectable anti HBs in this setting would
suggest unclear and possible infection, and needs exclusion).
c) Positive Hepatitis C virus antibody: Hepatitis C virus RNA by
polymerase chain reaction is necessary. Detectable Hepatitis C virus RNA
renders the subject ineligible.
If above antibody/antigen testing is not able to be obtained, positive
hepatitis B or C viral load
• Malignancy other than NSCLC within 3 years prior to randomization,
with the exception of those with a negligible risk of metastases or death
and treated with expected curative outcome.
• Major surgery within 28 days of study day 1
• Significant gastrointestinal disorder that results in significant
malabsorption, requirement for intravenous alimentation, or inability to
take oral medication.
• Significant cardiovascular disease, such as New York Heart Association
cardiac disease (Class II or greater), myocardial infarction within 6
months prior to study day 1, unstable arrhythmias or unstable angina.
• Severe infections within 4 weeks prior to randomization including, but
not limited to hospitalization for complications of infection, bacteremia
or severe pneumonia.
• Therapeutic oral or intravenous antibiotics within 2 weeks prior to
randomization. Prophylactic antibiotics are allowed with Amgen medical
monitor approval.
• Current CTCAE version 5.0 grade = 2 peripheral neuropathy
Prior/Concomitant Therapy
• Unresolved toxicities from prior anti-tumor therapy, defined as not
having resolved to CTCAE version 5.0 grade 0 or 1, or to levels dictated
in the eligibility criteria with the exception of alopecia (any grade
allowed) or toxicities from prior anti-tumor therapy that are considered
irreversible (defined as having been present and stable for > 6 months),
endocrine adverse events that are stably maintained on appropriate
replacement therapy.
• Anti-tumor therapy within 4 weeks of study day 1; Please note that
bisph
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method